I

s the FDA too business-friendly? Can spit reunite families? And should you feel bad for pharma lobbyists?

We discuss all that and more in the latest episode of “The Readout LOUD,” STAT’s biotech podcast. Tune in for a conversation with ProPublica’s Caroline Chen covering her deep dive into how the FDA is conceding more and more to the drug industry it regulates. Then we dig into the alluring idea of using 23andMe tests to help families torn apart at the border — and the legal and ethical issues that make it impractical. You’ll also hear from STAT’s Erin Mershon about how the thorny issue of biosimilars has made life awkward for biopharma in Washington, and we’ll explain why making money in China might be harder than the drug industry thinks.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy